OSTEO EFFECTS OF ANABOLIC STEROIDS
ANABOLIC STEROIDS & BONE REGENERATION:
Healthy adults may experience negative age-related changes in bone mineral density. These changes can lead to osteoporosis and arthritis which often cause bone breaks and joint pain. Sex steroids like testosterone and estrogen decline with age and play an important role in bone health. Replacement therapy using exogenous forms of these natural hormones may positively affect bone regeneration.
AGE & BONE LOSS:
Bone loss starts between the ages of 35 and 50 year in men and women and continues into old age in both sexes. The age‐related decrease in circulating concentrations of free testosterone, adrenal androgens, growth hormone and insulin‐like growth factor 1 may contribute to the observed reduction in bone formation and continuing bone loss with age in men.
ANTI-OSTEOPOROSIS – ANABOLIC STEROIDS:
Several anabolic steroids have been synthesized and some of them have been approved as a drug for anti-osteoporosis. Anabolic steroids have revealed the increased bone mineral content or bone mineral density at the radius, and the lumbar spine in osteoporosis patients. Anabolic steroids have also decreased fat mass with increase of lean body mass and muscle mass, and lessened bone pain in osteoporosis patients having bone fracture, which seem to be favourable effects for especially elder osteoporosis patients.
NEW BONE FORMATION:
Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents.
This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time.
POSTMENOPAUSAL WOMEN & OSTEOPOROSIS CURE:
Estrogen therapy (ET) and estrogen with progesterone hormone therapy (HT) are approved for the prevention of osteoporosis in postmenopausal women. ET and HT reduce bone loss, increase bone density in both the spine and hip, and reduce the risk of hip, spine and other fractures in postmenopausal women. ET and HT also relieve menopausal symptoms.